Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/17/20 (What's New)

Summary

  • STRIIVING study demonstrated that switching from virologically suppressive regimen (2 NRTIs plus PI, NNRTI, or INSTI) to single-tablet, once-daily abacavir/dolutegravir/lamivudine was noninferior to continuing baseline ART for maintenance of virologic suppression at Week 24[Trottier 2017]
  • NEAT-022 study showed that switching virologically suppressed patients with high cardiovascular risk from their current regimen to dolutegravir-based ART was noninferior and improved lipid profiles[Gatell 2017]
  • French study assessed the efficacy and safety of switching virologically suppressed patients from a regimen of dolutegravir plus abacavir/lamivudine (either as separate components or as a coformulated regimen) to bictegravir/emtricitabine/tenofovir AF[Molina 2018]

    Action required